VAERS Explorer
Back to explore

Report #2828654

Received Feb 27, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
71 yrs
State
ID
Recovered
Unknown
Vaccinated
May 26, 2022
Onset
Mar 1, 2024
Days to onset
645
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
COVID19COVID19 (COVID19 (PFIZER-BIONTECH))PFIZER\BIONTECH4—LA

Symptoms (2)

Blood triglyceridesIntervertebral disc disorder

Symptom narrative

4th dose 26May2022: Intervertebral disc Mar2024; This is a spontaneous report received from a Consumer or other non HCP. A 73-year-old female patient received BNT162b2 (BNT162B2), on 26May2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 71 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Acid Reflux" (unspecified if ongoing), notes: Acid Reflux 60's; "A-fib" (unspecified if ongoing), notes: A-fib 50's; "Anxiety" (unspecified if ongoing), notes: Anxiety 60's; "Arthritis" (unspecified if ongoing), notes: Arthritis 60's; "Asthma" (unspecified if ongoing), notes: Asthma 60's; "Balance problems" (unspecified if ongoing), notes: Balance problems 80's; "Blepharitis birth" (unspecified if ongoing); "Bronchitis" (unspecified if ongoing), notes: Bronchitis 60's; "Carpal tunnel both" (unspecified if ongoing), notes: Carpal tunnel both 80's; "Cataracts both", start date: 20May2015 (unspecified if ongoing); "C-diff", start date: 20Jun2015 (unspecified if ongoing); "Cervical degeneration" (unspecified if ongoing), notes: Cervical degeneration 60's; "Concussions", start date: 2016 (unspecified if ongoing), notes: Concussions 2016/2017; "Cholesterol" (unspecified if ongoing), notes: Cholesterol 70's; "Depression" (unspecified if ongoing), notes: Depression 60's; "Dermatofibroma", start date: 2014 (unspecified if ongoing); "Deviated septum", start date: 2012 (unspecified if ongoing); "Diverticulitis" (unspecified if ongoing), notes: Diverticulitis 80's; "Dizziness" (unspecified if ongoing), notes: Dizziness 60's; "Duodenal ulcers" (unspecified if ongoing), notes: Duodenal ulcers 60's; "Esophageal polyps", start date: 2017 (unspecified if ongoing); "Exema", start date: 2016 (unspecified if ongoing); "Fibrocystic disease" (unspecified if ongoing), notes: Fibrocystic disease 60's; "Essential tremors" (unspecified if ongoing), notes: Essential tremors 60's; "Fibromyalgia" (unspecified if ongoing), notes: Fibromyalgia 60's; "Gall bladder", start date: May2002 (unspecified if ongoing); "Gastritis" (unspecified if ongoing); "Hearing loss" (unspecified if ongoing); "IBS" (unspecified if ongoing), notes: IBS 80's; "Keratosis" (unspecified if ongoing), notes: Keratosis 90's; "Migraines" (unspecified if ongoing), notes: Migraines 60's; "Osteoporosis" (unspecified if ongoing), notes: Osteoporosis 80's; "Pancreatitis", start date: 2007 (unspecified if ongoing); "Panic attacks" (unspecified if ongoing), notes: Panic attacks 60's; "Proteins deficiency", start date: Mar2004 (unspecified if ongoing); "Sinusitis" (unspecified if ongoing), notes: Sinusitis 60's; "Sleep apnea", start date: Mar2004 (unspecified if ongoing); "Stroke", start date: Mar2004 (unspecified if ongoing); "Transcranial magnetic stimulation" (unspecified if ongoing), notes: TMS 60's. The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (DOSE 1, SINGLE, Location of injection/shot: Left Arm), administration date: 03Mar2021, when the patient was 70-year-old, for COVID-19 immunization; BNT162b2 (DOSE 2, SINGLE, Location of injection/shot: Left Arm), administration date: 26Mar2021, when the patient was 70-year-old, for COVID-19 immunization; BNT162b2 (DOSE 3 (BOOSTER), SINGLE, Location of injection/shot: Left Arm), administration date: 08Nov2021, when the patient was 71-year-old, for COVID-19 immunization. The following information was reported: INTERVERTEBRAL DISC DISORDER (non-serious) with onset Mar2024, outcome "unknown", described as "4th dose 26May2022: Intervertebral disc Mar2024". Relevant laboratory tests and procedures are available in the appropriate section. The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.

Medical history

Medical History/Concurrent Conditions: Acid reflux (esophageal) (Acid Reflux 60's); AFib (A-fib 50's); Anxiety (Anxiety 60's); Arthritis (Arthritis 60's); Asthma (Asthma 60's); Balance disorder (Balance problems 80's); Blepharitis; Blood cholesterol abnormal (Cholesterol 70's); Bronchitis (Bronchitis 60's); C.difficile colitis; Carpal tunnel syndrome (Carpal tunnel both 80's); Cataracts; Cervical disc degeneration (Cervical degeneration 60's); Concussion (Concussions 2016/2017); Depression (Depression 60's); Dermatofibroma; Diverticulitis (Diverticulitis 80's); Dizziness (Dizziness 60's); Duodenal ulcer (Duodenal ulcers 60's); Eczema; Esophageal polyp; Essential tremor (Essential tremors 60's); Fibrocystic disease of breast (Fibrocystic disease 60's); Fibromyalgia (Fibromyalgia 60's); Gallbladder disorder; Gastritis; Hearing loss; Irritable bowel syndrome (IBS 80's); Keratosis (Keratosis 90's); Migraine (Migraines 60's); Nasal septum deviation; Osteoporosis (Osteoporosis 80's); Pancreatitis; Panic attacks (Panic attacks 60's); Protein deficiency; Sinusitis (Sinusitis 60's); Sleep apnea; Stroke; Transcranial magnetic stimulation (TMS 60's)

Lab data

Test Name: Tyglycerides; Result Unstructured Data: Test Result:High; Comments: 70's